Drug intelligence / Profile preview

DHNP-2401

Development stage: Preclinical
Lead developer: Daehan Nupharm
Modality: Small Molecules

Overview

DHNP-2401 is a small molecule therapeutic candidate being developed by the South Korean pharmaceutical company Daehan Nupharm for the treatment of obesity. As of current pipeline reports, the drug is in the formulation research stage (제제연구), which involves optimizing the drug's delivery system and physical properties prior to clinical testing. While specific details regarding its biological target and mechanism of action have not been publicly disclosed, it is a key asset in Daehan Nupharm's metabolic disease portfolio, aimed at providing new options for weight management.

Beyond the preview

Go deeper on DHNP-2401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHNP-2401.

Explore the full profile